Patents by Inventor Wim Nerinckx

Wim Nerinckx has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240101647
    Abstract: Agents that bind to sarbecoviruses of multiple clades, neutralizing sarbecovirus infection, in particular neutralizing SARS-CoV-1 and SARS-CoV-2 infection. The agents bind to a unique epitope of the sarbecovirus ACE2-receptor binding domain (RBD) but do not inhibit binding of ACE2 with the RBD. Applications and uses of these agents are further disclosed.
    Type: Application
    Filed: February 7, 2022
    Publication date: March 28, 2024
    Inventors: Xavier SAELENS, Dorien DE VLIEGER, Iebe ROSSEY, Sieglinde DE CAE, Koen SEDEYN, Loes VAN SCHIE, Hannah EECKHAUT, Daria FIJALKOWSKA, Catelijne STORTELERS, Bert SCHEPENS, Nico CALLEWAERT, Han REMAUT, Wim NERINCKX, Kenny ROOSE, Dirk REITER
  • Patent number: 11891451
    Abstract: The present invention provides nucleotide sequences encoding polypeptides comprising immunoglobulin variable domains with engineered glycosylation acceptor sites. Specifically, the invention provides immunoglobulin variable domain proteins modified with selected glycans and specific glycan-conjugates thereof. Also provided herein are methods for the production of glycosylated immunoglobulin variable domains and glycan-conjugates thereof.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: February 6, 2024
    Assignees: VIB VZW, Universiteit Gent
    Inventors: Nico Callewaert, Bram Laukens, Loes Van Schie, Wander Van Breedam, Wim Nerinckx
  • Publication number: 20230227537
    Abstract: The present invention relates to the field of virology, more specifically to the field of zoonotic Coronaviruses. Specifically, the invention provides for binding agents specific for the spike protein receptor binding domain (RBD) of the SARS-Corona virus, more specifically for an epitope of the RBD present in a broad range of Sarbecoviruses and mutants thereof, even more specifically present in SARS-Cov and SARS-CoV-2 viruses. More specifically, the invention relates to compositions comprising antibodies capable of specifically binding and neutralizing SARS-Corona viruses.
    Type: Application
    Filed: February 5, 2021
    Publication date: July 20, 2023
    Inventors: Bert SCHEPENS, Xavier SAELENS, Nico CALLEWAERT, Dorien DE VLIEGER, Loes VAN SCHIE, Wim NERINCKX, Kenny ROOSE, Wander VAN BREEDAM, Hannah EECKHAUT, Daria FIJALKOWSKA, Chiara LONIGRO, Sieglinde DE CAE, Bruno DOMBRECHT, Catelijne STORTELERS, Johan NEYTS, Leen DELANG, Suzanne KAPTEIN, Joana DUARTE DA ROCHA PEREIRA, Barney GRAHAM, Jason MCLELLAN, Daniel WRAPP, Han REMAUT
  • Publication number: 20200148790
    Abstract: The present invention provides nucleotide sequences encoding polypeptides comprising immunoglobulin variable domains with engineered glycosylation acceptor sites. Specifically, the invention provides immunoglobulin variable domain proteins modified with selected glycans and specific glycan-conjugates thereof. Also provided herein are methods for the production of glycosylated immunoglobulin variable domains and glycan-conjugates thereof.
    Type: Application
    Filed: May 9, 2018
    Publication date: May 14, 2020
    Inventors: Nico Callewaert, Bram Laukens, Loes Van Schie, Wander Van Breedam, Wim Nerinckx